EU's CHMP reverses opinion on Gilead's inhaled aztreonam
02 July 2009
John Davis
Please Login to read the full article.
02 July 2009
John Davis
john.davis@informa.com
Gilead Science's nebulised antibiotic formulation, Cayston (aztreonam lysine) received a positive opinion from the EU's CHMP last week, for short-term use in cystic fibrosis patients, after a re-examination.
Cayston was turned down by the CHMP earlier this year, but Gilead asked for a...
Please Login to read the full article.
RELATED CONTENT
NEWS
- NovaBiotics reveals plans for cystic fibrosis drug after EU grants orphan status
- VCs dump $67.5M into Rempex (rump Mpex) for ESKAPE efflux pump inhibitors
- EMA's CHMP adopts positive opinion for Pharmaxis' cystic fibrosis drug
- Insmed plummets on FDA prolonged hold on Arikace programme
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
